

Gianfranco Ferraccioli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5690495/gianfranco-ferraccioli-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

269
papers

17,538
citations

58
h-index

128
g-index

305
ext. papers

20,868
ext. citations

4.9
avg, IF

5.93
L-index

#	Paper	IF	Citations
269	Immune-guided therapy of COVID-19.. <i>Cancer Immunology Research</i> , 2022 ,	12.5	2
268	Infectious agents breaking the immunological tolerance: The holy grail in rheumatoid arthritis (RA) reconsidered.. <i>Autoimmunity Reviews</i> , 2022 , 103102	13.6	0
267	Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry. <i>Clinical Rheumatology</i> , 2021 , 40, 4039-4047	3.9	0
266	RAASI, NSAIDs, antidiabetics, and anticoagulants: More data needed to be labeled as harmful or neutral in SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	0
265	Comprehensive review on intravertebral intraspinal, intrajoint, and intradiscal vacuum phenomenon: From anatomy and physiology to pathology. <i>Modern Rheumatology</i> , 2021 , 31, 303-311	3.3	4
264	Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. <i>Joint Bone Spine</i> , 2021 , 88, 105062	2.9	5
263	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 31-35	2.4	61
262	The pathogenesis of microthrombi in COVID-19 cannot be controlled by DOAC: NETosis should be the target. <i>Journal of Internal Medicine</i> , 2021 , 289, 420-421	10.8	7
261	Systemic Bone Density at Disease Onset Is Associated With Joint Erosion Progression in Early Naive to Treatment Rheumatoid Arthritis: A Prospective 12-Month Follow-Up Open-Label Study. <i>Frontiers in Medicine</i> , 2021 , 8, 613889	4.9	0
260	Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	2
259	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	6
258	Inclusion of Synovial Tissue-Derived Characteristics in a Nomogram for the Prediction of Treatment Response in Treatment-Naive Rheumatoid Arthritis Patients. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1601-1613	9.5	2
257	() as a Potential Driver of Molecular Mimicry and Inflammation in Rheumatoid Arthritis. <i>Frontiers in Medicine</i> , 2021 , 8, 671018	4.9	2
256	Comment on: Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2020 , 59, 1782-1783	3.9	1
255	Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 453-459	2.4	22
254	Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA. <i>Journal of Rheumatology</i> , 2020 , 47, 796-808	4.1	1
253	Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. <i>Nature Medicine</i> , 2020 , 26, 1295-1306	50.5	115

252	Basic immunology may lead to translational therapeutic rationale: SARS-CoV-2 and rheumatic diseases. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13342	4.6	8
251	Morbidity and Mortality From COVID-19 Are Not Increased Among Children or Patients With Autoimmune Rheumatic Disease-Possible Immunologic Rationale: Comment on the Article by Henderson et al. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1772-1774	9.5	1
250	Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations. <i>Clinical Immunology</i> , 2020 , 214, 108395	9	9
249	FRI0574 RENAL TISSUE EPIGENETIC BIOMARKERS CHARACTERIZATION IN PATIENTS WITH LUPUS NEPHRITIS AS PARAMETERS OF DISEASE ACTIVITY, REMISSION AND FLARE. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 889.2-890	2.4	
248	SAT0224 ANTIPHOSPHOLIPID ANTIBODIES AND VASCULAR RENAL LESIONS AS PROGNOSTIC FACTORS IN LUPUS NEPHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1055.3-1055	2.4	
247	THU0287 EVALUATION OF PREDICTIVE FACTORS OF WORSE PROGNOSIS IN LUPUS NEPHRITIS: FOCUS ON NEW PATHOGENETIC PATHWAYS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 370.3-370	2.4	
246	AB0102 SPECIALIZED PRO-RESOLVING MEDIATOR RECEPTORS AS INFLAMMATORY RESOLUTION BIOMARKERS IN RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1350.3-1350	2.4	
245	Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	6
244	Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies. <i>Frontiers in Medicine</i> , 2020 , 7, 553075	4.9	2
243	More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	2
242	Pulmonary intravascular coagulopathy in COVID-19 pneumonia. <i>Lancet Rheumatology, The</i> , 2020 , 2, e45814.2	4.2	6
241	Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. <i>Archives of Rheumatology</i> , 2020 , 35, 163-169	0.9	0
240	Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort. <i>Journal of Rheumatology</i> , 2020 , 47, 809-819	4.1	7
239	Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	5
238	Gut microbiota analysis in systemic sclerosis according to disease characteristics and nutritional status. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 125, 73-84	2.2	3
237	The B side of rheumatoid arthritis pathogenesis. <i>Pharmacological Research</i> , 2019 , 149, 104465	10.2	7
236	Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019 , 21, 116	5.7	12
235	Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study. <i>European Journal of Internal Medicine</i> , 2019 , 66, 57-61	3.9	7

234	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019 , 10, 296	5.6	17
233	Selective Inhibitors of T Cell Receptor Recognition of Antigen-MHC Complexes for Rheumatoid Arthritis. <i>ACS Medicinal Chemistry Letters</i> , 2019 , 10, 644-649	4.3	4
232	Microvascular heart involvement in systemic autoimmune diseases: The purinergic pathway and therapeutic insights from the biology of the diseases. <i>Autoimmunity Reviews</i> , 2019 , 18, 317-324	13.6	5
231	Measuring the T-cell down-regulation of TCR-zeta, ZAP-70 and CD28 in arthritis patients: An old tool for new biomarkers. <i>European Journal of Immunology</i> , 2019 , 49, 2195-2203	6.1	0
230	JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy. <i>Journal of Leukocyte Biology</i> , 2019 , 106, 1063-1068	6.5	27
229	Overweight/obesity affects histological features and inflammatory gene signature of synovial membrane of Rheumatoid Arthritis. <i>Scientific Reports</i> , 2019 , 9, 10420	4.9	8
228	Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a analysis of a phase III trial. <i>RMD Open</i> , 2019 , 5, e000934	5.9	5
227	Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study. <i>European Journal of Internal Medicine</i> , 2019 , 60, 46-53	3.9	29
226	Anti-Müllerian hormone serum levels in systemic lupus erythematosus patients: Influence of the disease severity and therapy on the ovarian reserve. <i>Endocrine</i> , 2019 , 63, 369-375	4	15
225	Rate of serious infections in spondyloarthritis patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 649-655	2.2	9
224	Free light chains of immunoglobulins in patients with systemic sclerosis: correlations with lung involvement and inflammatory milieu. <i>Journal of Clinical Pathology</i> , 2018 , 71, 620-625	3.9	11
223	Should rheumatoid factor (RF) (and antinuclear antibodies (ANA)) become routinary screening test for morbidities in the general population?: From the concept of "benign autoimmunity "to the concept of" autoimmunity as a red flag in preventive medicine"?. <i>Autoimmunity Reviews</i> , 2018 , 17, 636-638	13.6	2
222	Driving chronicity in rheumatoid arthritis: perpetuating role of myeloid cells. <i>Clinical and Experimental Immunology</i> , 2018 , 193, 13-23	6.2	21
221	Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression. <i>Arthritis Research and Therapy</i> , 2018 , 20, 75	5.7	24
220	Interleukin-6 and IgA-rheumatoid factor are crucial for baseline erosiveness, and anti-citrullinated peptide antibodies for radiographic progression in early rheumatoid arthritis treated according to a treat-to-target strategy. <i>Scandinavian Journal of Rheumatology</i> , 2018 , 47, 351-359	1.9	6
219	The UltraSound-CLinical ARthritis Activity (US-CLARA) index: Properties of a new composite disease activity index for rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 47, 619-629	5.3	9
218	Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA. <i>Clinical Rheumatology</i> , 2018 , 37, 315-321	3.9	27
217	Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. <i>Joint Bone Spine</i> , 2018 , 85, 455-459	2.9	11

216	Prevalence and Determinants of Peripheral Microvascular Endothelial Dysfunction in Rheumatoid Arthritis Patients: A Multicenter Cross-Sectional Study. <i>Mediators of Inflammation</i> , 2018 , 2018, 6548715	4.3	19
215	Synovial Predictors of Differentiation to Definite Arthritis in Patients With Seronegative Undifferentiated Peripheral Inflammatory Arthritis: microRNA Signature, Histological, and Ultrasound Features. <i>Frontiers in Medicine</i> , 2018 , 5, 186	4.9	17
214	Abatacept in the treatment of psoriatic arthritis: biological and clinical profiles of the responders. <i>Immunotherapy</i> , 2018 , 10, 807-821	3.8	8
213	Chemerin and PEDF Are Metaflammation-Related Biomarkers of Disease Activity and Obesity in Rheumatoid Arthritis. <i>Frontiers in Medicine</i> , 2018 , 5, 207	4.9	19
212	The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts. <i>Autoimmunity Reviews</i> , 2018 , 17, 1251-1258	13.6	1
211	Unmet Needs in the Treatment of RA in the Era of Jak-i: IDRA (Italian Delphi Rheumatoid Arthritis) Consensus. <i>BioMed Research International</i> , 2018 , 2018, 3878953	3	1
210	Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis. <i>RMD Open</i> , 2018 , 4, e000667	5.9	11
209	2016 update of the EULAR recommendations for the management of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 948-959	2.4	243
208	Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1228-1236	2.4	37
207	Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis: A case report treated with high doses (8 mg/kg/d) of anakinra. <i>Medicine (United States)</i> , 2017 , 96, e6656	1.8	35
206	MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis. <i>Nature Communications</i> , 2017 , 8, 15877	17.4	51
205	QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic risk. <i>International Journal of Cardiology</i> , 2017 , 239, 33	3.2	15
204	Baseline Shoulder Ultrasonography Is Not a Predictive Marker of Response to Glucocorticoids in Patients with Polymyalgia Rheumatica: A 12-month Followup Study. <i>Journal of Rheumatology</i> , 2017 , 44, 241-247	4.1	7
203	MicroRNA-155-at the Critical Interface of Innate and Adaptive Immunity in Arthritis. <i>Frontiers in Immunology</i> , 2017 , 8, 1932	8.4	105
202	B cell activating factor (BAFF) and BAFF receptors: fakes and facts. <i>Clinical and Experimental Immunology</i> , 2017 , 190, 291-292	6.2	16
201	Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2017 , 36, 2655-2665	3.9	20
200	Is ACPA positivity the main driver for rheumatoid arthritis treatment? Pros and cons. <i>Autoimmunity Reviews</i> , 2017 , 16, 1096-1102	13.6	14
199	Clinical heterogeneity of SAPHO syndrome: challenging diagnose and treatment. <i>Clinical Rheumatology</i> , 2017 , 36, 2151-2158	3.9	46

198	An autosomal recessive DNASE1L3-related autoimmune disease with unusual clinical presentation mimicking systemic lupus erythematosus. <i>Lupus</i> , 2017 , 26, 768-772	2.6	24
197	Life-threatening arrhythmias in a scleroderma patient: the role of myocardial inflammation in arrhythmic outburst. <i>Scandinavian Journal of Rheumatology</i> , 2017 , 46, 78-80	1.9	17
196	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2017 , 8, 369	5.6	68
195	The Role of High-Mobility Group Box-1 and Its Crosstalk with Microbiome in Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2017 , 2017, 5230374	4.3	9
194	Environmental Pollution by Benzene and PM and Clinical Manifestations of Systemic Sclerosis: A Correlation Study. <i>International Journal of Environmental Research and Public Health</i> , 2017 , 14,	4.6	9
193	Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced Osteoporosis TOol (GIOTTO) study. <i>Reumatismo</i> , 2017 , 69, 30-39	1.1	24
192	Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 660-665	2.2	5
191	Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 919-928	2.2	
190	Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 1018-1028	2.2	7
189	Comment on "Tumor necrosis factor- α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study". <i>Clinical Rheumatology</i> , 2016 , 35, 839-40	3.9	1
188	Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. <i>Clinical Rheumatology</i> , 2016 , 35, 2649-2656	3.9	14
187	Thymosin α 1 and Sjögren's syndrome: saliva proteomics and minor salivary glands expression. <i>Arthritis Research and Therapy</i> , 2016 , 18, 229	5.7	4
186	MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis. <i>Nature Communications</i> , 2016 , 7, 12970	17.4	72
185	Do we need to apply a T2T strategy even in ACPA-negative early rheumatoid arthritis? YES. <i>RMD Open</i> , 2016 , 2, e000263	5.9	3
184	The role of high-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on vascular endothelial growth factor. <i>Clinical and Experimental Immunology</i> , 2016 , 184, 62-72	6.2	12
183	Tapering and discontinuation of TNF-blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission. <i>Arthritis Research and Therapy</i> , 2016 , 18, 39	5.7	46
182	Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey. <i>Arthritis Research and Therapy</i> , 2016 , 18, 78	5.7	35
181	Biomolecular features of inflammation in obese rheumatoid arthritis patients: management considerations. <i>Expert Review of Clinical Immunology</i> , 2016 , 12, 751-62	5.1	9

180	Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: results by Italian DELphi in psoriatic Arthritis (IDEA). <i>Reumatismo</i> , 2016 , 68, 126-136	1.1	12
179	Prognostic Role of Ventricular Ectopic Beats in Systemic Sclerosis: A Prospective Cohort Study Shows ECG Indexes Predicting the Worse Outcome. <i>PLoS ONE</i> , 2016 , 11, e0153012	3.7	31
178	Immunosuppressive Therapy (Methotrexate or Cyclophosphamide) in Combination with Corticosteroids in the Treatment of Giant Cell Arteritis: Comparison with Corticosteroids Alone. <i>Journal of the American Geriatrics Society</i> , 2016 , 64, 672-374	5.6	4
177	Weight Loss, The Obesity Paradox in Rheumatoid Arthritis: Is It a Paradox? Comment on the Article by Baker et al. <i>Arthritis and Rheumatology</i> , 2016 , 68, 553	9.5	
176	Is Citrullination Required for the Presence of Restricted Clonotypes Reacting With Type II Collagen? Comment on the Article by Chemin et al. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2052-3	9.5	2
175	When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). <i>RMD Open</i> , 2016 , 2, e000221	5.9	26
174	Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016 , 18, 294	5.7	22
173	The prognostic significance of the Birmingham Vasculitis Activity Score (BVAS) with systemic vasculitis patients transferred to the intensive care unit (ICU). <i>Medicine (United States)</i> , 2016 , 95, e5506	1.8	11
172	L'indice de masse corporelle n'a pas d'impact sur la réponse à l'abatacept sous-cutané intraveineux chez les patients souffrant de polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2016 , 83, A167-A168	0.1	
171	Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. <i>Clinical Rheumatology</i> , 2016 , 35, 1683-9	3.9	52
170	Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2527-39	9.5	92
169	CTLA-4 Ig as an effective treatment in a patient with type I diabetes mellitus and seropositive rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 315-7	2.2	4
168	Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. <i>Rheumatology</i> , 2015 , 54, 792-7	3.9	55
167	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 963-9	2.4	27
166	OP0274 Cryoglobulinemic Vasculitis and Primary Sjögren's Syndrome are Independent Risk Factors for Lymphoma in a Large Worldwide Population of Patients with Positive Serum Cryoglobulins. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 175.3-176	2.4	
165	Tumour-associated antigens in systemic sclerosis patients with interstitial lung disease: association with lung involvement and cancer risk. <i>Rheumatology</i> , 2015 , 54, 1991-9	3.9	11
164	Quality indicators in rheumatoid arthritis: results from the METEOR database. <i>Rheumatology</i> , 2015 , 54, 1630-9	3.9	18
163	Collagen Specific T-Cell Repertoire and HLA-DR Alleles: Biomarkers of Active Refractory Rheumatoid Arthritis. <i>EBioMedicine</i> , 2015 , 2, 2037-45	8.8	26

162	Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR Database. <i>Journal of Clinical Rheumatology</i> , 2015 , 21, 349-54 ^{1,1}		6
161	Computer-aided quantification of interstitial lung disease from high resolution computed tomography images in systemic sclerosis: correlation with visual reader-based score and physiologic tests. <i>BioMed Research International</i> , 2015 , 2015, 834262	3	29
160	Detection of bone erosions in early rheumatoid arthritis: 3D ultrasonography versus computed tomography. <i>Clinical Rheumatology</i> , 2015 , 34, 1181-6	3.9	12
159	Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. <i>Rheumatology</i> , 2015 , 54, 891-8	3.9	93
158	Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 44, 428-36	5.3	102
157	Position paper of Italian rheumatologists on the use of biosimilar drugs. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 1-4	2.2	21
156	Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 449-56	2.2	51
155	Body weight, gender and response to TNF- β blockers in axial spondyloarthritis. <i>Rheumatology</i> , 2014 , 53, 875-81	3.9	83
154	Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 43, 526-35	5.3	91
153	Response to letter by Aramugakani et al. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, e21	2.4	1
152	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register. <i>Joint Bone Spine</i> , 2014 , 81, 508-12	2.9	15
151	Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register). <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, e31	2.4	7
150	Validation of the classification criteria for cryoglobulinaemic vasculitis. <i>Rheumatology</i> , 2014 , 53, 2209-13	3.9	55
149	THU0525 Metaflammation, PEDF and Chemerin: Potential Systemic Factors Which Link Obesity to Response to Therapy in Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 364.3-365 ^{2,4}		1
148	Memory B cell subsets and plasmablasts are lower in early than in long-standing rheumatoid arthritis. <i>BMC Immunology</i> , 2014 , 15, 28	3.7	19
147	Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases). <i>Frontiers in Immunology</i> , 2014 , 5, 576	8.4	82
146	Toll-like receptor 4 mediates endothelial cell activation through NF- β but is not associated with endothelial dysfunction in patients with rheumatoid arthritis. <i>PLoS ONE</i> , 2014 , 9, e99053	3.7	27
145	The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program. <i>Clinical and Experimental Rheumatology</i> , 2014 , 32, 869-77	2.2	39

144	Cilostazol improves the response to ischemia in diabetic mice by a mechanism dependent on PPAR α <i>Molecular and Cellular Endocrinology</i> , 2013 , 381, 80-7	4.4	17
143	<i>Porphyromonas gingivalis</i> and the pathogenesis of rheumatoid arthritis: analysis of various compartments including the synovial tissue. <i>Arthritis Research and Therapy</i> , 2013 , 15, R66	5.7	43
142	The role of biosimilars in the treatment of rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 322-8	2.4	134
141	Obesity and reduction of the response rate to anti-tumor necrosis factor β in rheumatoid arthritis: an approach to a personalized medicine. <i>Arthritis Care and Research</i> , 2013 , 65, 94-100	4.7	137
140	Tofacitinib for rheumatoid arthritis. <i>Lancet, The</i> , 2013 , 381, 1812	4.0	4
139	Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 583-9	2.4	68
138	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 482-92	2.4	87
137	Temporal ultrasonography findings in temporal arteritis: early disappearance of halo sign after only 2 days of steroid treatment. <i>Rheumatology</i> , 2013 , 52, 622	3.9	21
136	Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 858-62	2.4	91
135	FRI0096 Haq baseline values in an international registry of ra patients during the era of biologic therapies: the 2013 meteor database.. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A402.1-A402	2.4	
134	AB0770 Rheuma-card: involvement of the patient through a secure systems access into the treat to target strategy in rheumatology.. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A1025.1-A1025	2.4	
133	SAT0199 An estimate of the proportion of patients with sle receiving off-label treatment with rituximab in european countries. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 539.1-539	2.4	
132	THU0532 Distribution of Body Mass Index and Metabolic Syndrome in Patients with Inflammatory Autoimmune Diseases from a Single Italian Centre. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A344.1-A344	2.4	1
131	SAT0175 Results of the Classification Criteria for Cryoglobulinemic Vasculitis Validation Study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A640.2-A641	2.4	
130	OP0178 The Body Mass Index: A Determinant of Remission in Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A113.2-A113	2.4	2
129	AB0465 Etanercept therapy in rheumatoid arthritis patients with moderate or severe disease activity. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 664.5-664	2.4	1
128	To switch or not to switch after a poor response to a TNF α blocker? It is not only a matter of ACR20 OR ACR50. <i>Autoimmunity Reviews</i> , 2012 , 11, 558-62	13.6	15
127	Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs. <i>Rheumatology</i> , 2012 , 51 Suppl 5, v12-21	3.9	14

126	Should we consider tumor necrosis factor as the only target in spondyloarthritides?. <i>Journal of rheumatology Supplement, The</i> , 2012 , 89, 94-6		2
125	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. <i>Autoimmunity Reviews</i> , 2012 , 12, 225-9	13.6	125
124	Colour Doppler ultrasonography evaluation of vascularization in the wrist and finger joints in rheumatoid arthritis patients and healthy subjects. <i>European Journal of Radiology</i> , 2012 , 81, 1834-8	4.7	31
123	The human salivary proteome: a critical overview of the results obtained by different proteomic platforms. <i>Expert Review of Proteomics</i> , 2012 , 9, 33-46	4.2	46
122	Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis. <i>PLoS ONE</i> , 2012 , 7, e40362	3.7	28
121	Association between the response to B cell depletion therapy and the allele*2 of the HS1,2A enhancer in seropositive rheumatoid arthritis patients. <i>Reumatismo</i> , 2012 , 64, 368-73	1.1	4
120	Brief report: successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicenter study. <i>Arthritis and Rheumatism</i> , 2012 , 64, 1970-7		112
119	Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease. <i>Clinical Respiratory Journal</i> , 2012 , 6, 9-17	1.7	33
118	Polymorphisms of the IgH enhancer HS1.2 and risk of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1309-15	2.4	19
117	ZAP-70+ B cell subset influences response to B cell depletion therapy and early repopulation in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2012 , 39, 2276-85	4.1	5
116	A vascular endothelial growth factor deficiency characterises scleroderma lung disease. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1461-5	2.4	9
115	Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. <i>Rheumatology</i> , 2012 , 51, 157-68	3.9	72
114	Biologics use in sle in 23 centers [Data from the international registry for biologics in SLE. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, A9.1-A9	2.4	1
113	Rheumatologic Symptoms in Patients with Mixed Cryoglobulinemia 2012 , 185-190		
112	Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2012 , 30, S48-52	2.2	25
111	Rheumatoid arthritis and Alzheimer's disease: genetic and epigenetic links in inflammatory regulation. <i>Discovery Medicine</i> , 2012 , 14, 379-88	2.5	18
110	PTPN22 1858C>T polymorphism distribution in Europe and association with rheumatoid arthritis: case-control study and meta-analysis. <i>PLoS ONE</i> , 2011 , 6, e24292	3.7	38
109	B-cell subsets in the joint compartments of seropositive and seronegative rheumatoid arthritis (RA) and No-RA arthritides express memory markers and ZAP70 and characterize the aggregate pattern irrespectively of the autoantibody status. <i>Molecular Medicine</i> , 2011 , 17, 901-9	6.2	24

108	GISEA: an Italian biological agents registry in rheumatology. <i>Reumatismo</i> , 2011 , 63, 155-64	1.1	19
107	B cells in systemic sclerosis: a possible target for therapy. <i>Autoimmunity Reviews</i> , 2011 , 10, 624-30	13.6	57
106	The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. <i>Autoimmunity Reviews</i> , 2011 , 10, 582-9	13.6	71
105	Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis. <i>Clinical Immunology</i> , 2011 , 138, 107-16	9	45
104	Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review. <i>Clinical Rheumatology</i> , 2011 , 30, 1265-75	3.9	72
103	Pathogenetic, clinical and pharmaco-economic assessment in rheumatoid arthritis (RA). <i>Internal and Emergency Medicine</i> , 2011 , 6 Suppl 1, 11-5	3.7	13
102	Thymosins and interstitial lung disease: study of a scleroderma cohort with a one-year follow-up. <i>Respiratory Research</i> , 2011 , 12, 22	7.3	17
101	Proteome analysis of biological fluids from autoimmune-rheumatological disorders. <i>Proteomics - Clinical Applications</i> , 2011 , 5, 78-89	3.1	13
100	Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. <i>Arthritis Care and Research</i> , 2011 , 63, 711-20	4.7	33
99	Atlantoepistrophic magnetic resonance imaging involvement in early rheumatoid arthritis: an aggressive tight control therapy not fully arresting the disease. <i>Arthritis Care and Research</i> , 2011 , 63, 1629-33	4.7	2
98	Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 172-5	2.4	135
97	Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1292-5	2.4	56
96	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 909-20	2.4	308
95	B cell receptor repertoire analysis in clinically involved and uninvolved skin of systemic sclerosis patients treated with CD20 depletion therapy: baseline and follow-up. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, A62-A63	2.4	
94	The need for personalised medicine for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 4-7	2.4	67
93	Adiposity, joint and systemic inflammation: the additional risk of having a metabolic syndrome in rheumatoid arthritis. <i>Swiss Medical Weekly</i> , 2011 , 141, w13211	3.1	17
92	The potential role of Th17 in mediating the transition from acute to chronic autoimmune inflammation: rheumatoid arthritis as a model. <i>Discovery Medicine</i> , 2011 , 11, 413-24	2.5	31
91	Interleukin-1 and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis. <i>Molecular Medicine</i> , 2010 , 16, 552-7	6.2	75

90	Endothelial progenitors in pulmonary hypertension: new pathophysiology and therapeutic implications. <i>European Respiratory Journal</i> , 2010 , 35, 418-25	13.6	44
89	Diagnostic performance of anti-citrullinated peptide antibodies for the diagnosis of rheumatoid arthritis: the relevance of likelihood ratios. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010 , 48, 829-34	5.9	15
88	B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. <i>Arthritis Research and Therapy</i> , 2010 , 12, R54	5.7	127
87	Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. <i>Arthritis Research and Therapy</i> , 2010 , 12, R42	5.7	160
86	2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1580-8	2.4	2158
85	Interstitial granulomatous dermatitis in rheumatoid arthritis responsive to etanercept. <i>Clinical Rheumatology</i> , 2010 , 29, 99-101	3.9	25
84	MR imaging of atlantoaxial joint in early rheumatoid arthritis. <i>Radiologia Medica</i> , 2010 , 115, 1111-20	6.5	15
83	Proteomic approaches to Sjögren's syndrome: a clue to interpret the pathophysiology and organ involvement of the disease. <i>Autoimmunity Reviews</i> , 2010 , 9, 622-6	13.6	22
82	Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. <i>Arthritis and Rheumatism</i> , 2010 , 62, 674-82		92
81	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2582-91		182
80	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2569-81		4825
79	Modeling the ternary complex TCR-Vbeta/CollagenII(261-273)/HLA-DR4 associated with rheumatoid arthritis. <i>PLoS ONE</i> , 2010 , 5, e11550	3.7	26
78	Development of a five-year mortality model in systemic sclerosis patients by different analytical approaches. <i>Clinical and Experimental Rheumatology</i> , 2010 , 28, S18-27	2.2	44
77	The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 584-90	2.4	32
76	Synovial B cells of rheumatoid arthritis express ZAP-70 which increases the survival and correlates with the inflammatory and autoimmune phenotype. <i>Clinical Immunology</i> , 2009 , 131, 98-108	9	11
75	Improved endothelial function after endothelin receptor blockade in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1840-4		15
74	Skin ulcers in systemic sclerosis: determinants of presence and predictive factors of healing. <i>Journal of the American Academy of Dermatology</i> , 2009 , 60, 426-35	4.5	60
73	Function and dysfunction of dendritic cells in autoimmune rheumatic diseases. <i>Human Immunology</i> , 2009 , 70, 360-73	2.3	14

72	ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. <i>Arthritis Research and Therapy</i> , 2009 , 11, R163	5.7	22
71	Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment. <i>Drugs and Aging</i> , 2009 , 26, 395-402	4.7	25
70	Citrullination: the loss of tolerance and development of autoimmunity in rheumatoid arthritis. <i>Reumatismo</i> , 2008 , 60, 85-94	1.1	15
69	Renal interstitial cells, proteinuria and progression of lupus nephritis: new frontiers for old factors. <i>Lupus</i> , 2008 , 17, 533-40	2.6	22
68	Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. <i>Arthritis Research and Therapy</i> , 2008 , 10, R30	5.7	308
67	Chapter 8 Gastrointestinal Involvement in Systemic Vasculitis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2008 , 8, 83-298	0.3	
66	Infections, rheumatism and autoimmunity. <i>Future Rheumatology</i> , 2008 , 3, 223-225		1
65	TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2008 , 27, 833-9	3.9	67
64	B cell depletion and a T cell-targeted therapy allows to control the sudden onset of diabetes and lupus, without steroids. <i>Acta Diabetologica</i> , 2008 , 45, 195-6	3.9	1
63	Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. <i>Arthritis and Rheumatism</i> , 2008 , 59, 32-41		76
62	Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2642-51		135
61	Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008 , 35, 1256-64	4.1	87
60	Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. <i>Journal of Rheumatology</i> , 2008 , 35, 1944-9	4.1	75
59	Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 3896-908		270
58	Infections, B cell receptor activation and autoimmunity: different check-point impairments lead to autoimmunity, clonal B cell expansion and fibrosis in different immunological settings. <i>Autoimmunity Reviews</i> , 2007 , 7, 109-13	13.6	23
57	Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 249-52	2.4	36
56	Pharmacogenetic of antirheumatic treatments: clinical implications. <i>Pharmacogenomics Journal</i> , 2007 , 7, 2-9	3.5	5
55	B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection. <i>Rheumatology</i> , 2007 , 46, 37-43	3.9	85

54	Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1210-5	2.4	22
53	Analysis of response to infliximab in ankylosing spondylitis according to the axial and/or peripheral involvement: autoantibodies and drop outs are more frequent in the peripheral subset. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 427-8	2.4	2
52	EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCSIT). <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 34-45	2.4	508
51	Consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 143-50	2.4	142
50	Mycophenolate mofetil and intravenous dexamethasone in the treatment of persistent lupus myelitis. <i>Journal of Rheumatology</i> , 2007 , 34, 588-91	4.1	14
49	Hepatocyte growth factor and transforming growth factor beta1 ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis. <i>Arthritis and Rheumatism</i> , 2006 , 54, 3633-9		17
48	Lupus anticoagulant and ischemic myocardial microangiopathy in rheumatoid arthritis. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006 , 3, 339-43; quiz following 343		0
47	A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006 , 1, 925-32	6.9	119
46	Pharmacogenetics, Target Molecules, and Biological Anti-Rheumatic Drugs in Autoimmune/Chronic Inflammatory Rheumatic Diseases. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2006 , 4, 105-111		
45	Efficacy of cyclosporin-A in the long-term management of thrombocytopenia associated with systemic lupus erythematosus. <i>Lupus</i> , 2006 , 15, 76-9	2.6	25
44	IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. <i>Pharmacogenomics</i> , 2006 , 7, 683-95	2.6	62
43	Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. <i>Rheumatology</i> , 2006 , 45, 842-6	3.9	140
42	Osteoporosis and bone metabolism in postmenopausal women with osteoarthritis of the hand. <i>Menopause</i> , 2006 , 13, 462-6	2.5	22
41	Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 275-81	6.1	45
40	Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. <i>Respiratory Research</i> , 2005 , 6, 96	7.3	51
39	-238 and +489 TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis. <i>Immunology Letters</i> , 2005 , 96, 103-8	4.1	30
38	TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. <i>Autoimmunity Reviews</i> , 2005 , 4, 153-61	13.6	99
37	Pharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology. <i>Pharmacogenomics</i> , 2004 , 5, 1107-16	2.6	6

36	Thrombogenicity of TNF alpha in rheumatoid arthritis defined through biological probes: TNF alpha blockers. <i>Autoimmunity Reviews</i> , 2004 , 3, 261-6	13.6	27
35	<i>Helicobacter pylori</i> associated antigastric autoantibodies: role in Sjögren's syndrome gastritis. <i>Helicobacter</i> , 2004 , 9, 46-53	4.9	25
34	Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. <i>Annals of Internal Medicine</i> , 2004 , 141, 493-500	8	134
33	Efficacy and safety of rituximab in type II mixed cryoglobulinemia. <i>Blood</i> , 2003 , 101, 3827-34	2.2	392
32	Extrasalivary lymphoma development in Sjögren's syndrome: clonal evolution from parotid gland lymphoproliferation and role of local triggering. <i>Arthritis and Rheumatism</i> , 2003 , 48, 3181-6		37
31	Lack of Hcv Infection in Malignant, Cells Refutes the Hypothesis of a Direct Transforming Action of the Virus in the Pathogenesis of Hcv-Associated B-Cell Nhl's. <i>Tumori</i> , 2002 , 88, 400-406	1.7	17
30	Salivary gland B cell lymphoproliferative disorders in Sjögren's syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkins's lymphomas. <i>European Journal of Immunology</i> , 2002 , 32, 903-10	6.1	90
29	Rituximab for the treatment of type II mixed cryoglobulinemia. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2252-4; author reply 2254-5		47
28	Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2029-33		219
27	Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. <i>Annals of the Rheumatic Diseases</i> , 2002 , 61, 358-61	2.4	69
26	Absence of human parvovirus B19 DNA in myoepithelial sialadenitis of primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2002 , 61, 855-6	2.4	7
25	Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. <i>British Journal of Rheumatology</i> , 2002 , 41, 1346-56		99
24	Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2002 , 29, 29-33	4.1	41
23	Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2002 , 29, 1847-50	4.1	46
22	True primary Sjögren's syndrome in a subset of patients with hepatitis C infection: a model linking chronic infection to chronic sialadenitis. <i>Israel Medical Association Journal</i> , 2002 , 4, 1101-5	0.9	36
21	Haematopoietic stem cell transplantation (HSCT) in a patient with Sjögren's syndrome and lung malt lymphoma cured lymphoma not the autoimmune disease. <i>Annals of the Rheumatic Diseases</i> , 2001 , 60, 174-6	2.4	17
20	Preliminary classification of nonmalignant B cell proliferation in Sjögren's syndrome: perspectives on pathobiology and treatment based on an integrated clinico-pathologic and molecular study approach. <i>Blood Cells, Molecules, and Diseases</i> , 2001 , 27, 757-66	2.1	31
19	Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. <i>Arthritis and Rheumatism</i> , 2000 , 43, 94-102		126

18	Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: viral detection in gastric low-grade lymphoma associated with autoimmune disease and in chronic gastritis. <i>Hepatology</i> , 2000 , 31, 182-9	11.2	77
17	Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus. <i>International Journal of Clinical and Laboratory Research</i> , 2000 , 30, 67-73		30
16	Cyclosporine A pharmacokinetics in rheumatoid arthritis patients after 6 months of methotrexate therapy. <i>Pharmacological Research</i> , 1999 , 40, 483-6	10.2	5
15	Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 1997 , 40, 318-31		91
14	Widespread clonal B-cell disorder in Sjögren's syndrome predisposing to Helicobacter pylori-related gastric lymphoma. <i>Gastroenterology</i> , 1996 , 110, 1969-74	13.3	36
13	Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1006-15		72
12	Increase of bone mineral density and anabolic variables in patients with rheumatoid arthritis resistant to methotrexate after cyclosporin A therapy. <i>Journal of Rheumatology</i> , 1996 , 23, 1539-42	4.1	16
11	Hepatitis C virus within a malignant lymphoma lesion in the course of type II mixed cryoglobulinemia. <i>Blood</i> , 1995 , 86, 1887-1892	2.2	152
10	The Relevance of VDJ PCR Protocols in Detecting B-Cell Clonal Expansion in Lymphomas and Other Lymphoproliferative Disorders. <i>Tumori</i> , 1995 , 81, 405-409	1.7	13
9	Cyclosporin A increases somatomedin C insulin-like growth factor I levels in chronic rheumatic diseases. <i>Journal of Rheumatology</i> , 1995 , 22, 1060-4	4.1	5
8	Local cytokine expression in the progression toward B cell malignancy in Sjögren's syndrome. <i>Journal of Rheumatology</i> , 1995 , 22, 1674-80	4.1	23
7	Mild sialoadenitis: a common finding in patients with hepatitis C virus infection. <i>Scandinavian Journal of Gastroenterology</i> , 1994 , 29, 940-2	2.4	46
6	Somatomedin C (insulin-like growth factor 1) levels decrease during acute changes of stress related hormones. Relevance for fibromyalgia. <i>Journal of Rheumatology</i> , 1994 , 21, 1332-4	4.1	20
5	The polymerase chain reaction detects B cell clonalities in patients with Sjögren's syndrome and suspected malignant lymphoma. <i>Journal of Rheumatology</i> , 1994 , 21, 1497-501	4.1	24
4	The Chronic Arthritis Systemic Index: a nomogram to assess the activity and severity of chronic arthritis. <i>Arthritis and Rheumatism</i> , 1993 , 36, 1180-1		5
3	Peripheral neuropathy in essential mixed cryoglobulinaemia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1992 , 55, 116-20	5.5	48
2	Indomethacin-related serum sickness-like illness with IgM lambda cryoparaprotein?. <i>Acta Haematologica</i> , 1985 , 73, 45-6	2.7	
1	Controlled multicenter trial of tiopronin and d-penicillamine for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1982 , 25, 923-9		21

